Literature DB >> 12756503

Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI.

Tohoru Takeda, Jin Wu, Yuko Fumikura, Keiji Iida, Satoru Kawano, Iwao Yamaguchi, Yuji Itai.   

Abstract

The diagnostic value of technetium-99m tetrofosmin (TF) washout in hypertrophic cardiomyopathy (HCM) was examined by investigating its relation to the metabolic abnormality depicted by iodine-123 beta-methyl- p-iodophenylpentadecanoic acid (BMIPP) uptake and the left ventricular (LV) myocardial wall thickness as measured by magnetic resonance imaging (MRI). TF washout was evaluated in 31 patients with HCM and 23 normal control subjects using 30-min (early) and 3-h (delayed) TF single-photon emission tomography images. The LV myocardial wall was divided into 19 segments and the percentage TF washout, regional BMIPP uptake and LV wall thickness were measured in each segment. Mean TF washout in the patients with HCM was significantly faster than that in normal control subjects (23.7+/-5.7 vs 13.4+/-4.1, P<0.0001). In the patients with HCM, TF washout showed an excellent correlation with MRI wall thickness ( r=0.82, P<0.0001) and a good inverse correlation with regional BMIPP uptake ( r=-0.72, P<0.0001). In addition, a good linear correlation was observed between TF uptake and MRI wall thickness in the 19 regional segments. In conclusion, the degree of TF washout corresponds well with the severity of myocardial wall thickness and the degree of metabolic abnormality in patients with HCM. These results suggest that enhanced TF washout might provide additional clinical information regarding metabolic alterations in HCM.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756503     DOI: 10.1007/s00259-003-1163-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration.

Authors:  Y Fujibayashi; Y Yonekura; Y Takemura; K Wada; K Matsumoto; N Tamaki; K Yamamoto; J Konishi; A Yokoyama
Journal:  J Nucl Med       Date:  1990-11       Impact factor: 10.057

2.  Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  M Grover-McKay; M Schwaiger; J Krivokapich; J K Perloff; M E Phelps; H R Schelbert
Journal:  J Am Coll Cardiol       Date:  1989-02       Impact factor: 24.094

3.  Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells.

Authors:  A S Arbab; K Koizumi; K Toyama; T Arai; T Araki
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

4.  Time course evaluation of myocardial perfusion after reperfusion therapy by 99mTc-tetrofosmin SPECT in patients with acute myocardial infarction.

Authors:  R Tanaka; T Nakamura
Journal:  J Nucl Med       Date:  2001-09       Impact factor: 10.057

5.  Fatty acid metabolic imaging with iodine-123-BMIPP for the diagnosis of coronary artery disease.

Authors:  S Fujiwara; Y Takeishi; H Atsumi; K Takahashi; H Tomoike
Journal:  J Nucl Med       Date:  1997-02       Impact factor: 10.057

6.  Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy.

Authors:  C Kurata; K Tawarahara; T Taguchi; S Aoshima; A Kobayashi; N Yamazaki; H Kawai; M Kaneko
Journal:  J Nucl Med       Date:  1992-01       Impact factor: 10.057

7.  Heterogeneous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy.

Authors:  Y Takeishi; J Chiba; S Abe; I Tonooka; A Komatani; H Tomoike
Journal:  Eur J Nucl Med       Date:  1992

8.  Studies of fatty acid metabolism with positron emission tomography in patients with cardiomyopathy.

Authors:  H Sochor; H R Schelbert; M Schwaiger; E Henze; M E Phelps
Journal:  Eur J Nucl Med       Date:  1986

9.  Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines.

Authors:  A S Arbab; K Koizumi; K Toyama; T Araki
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

10.  Myocardial scintigraphic study with 123I 15-(p-iodophenyl)-3(R,S)-methylpentadecanoic acid in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; H Yoshio; H Ino; J Taki; K Nakajima; H Bunko; R Takeda
Journal:  Int J Cardiol       Date:  1996-04-19       Impact factor: 4.164

View more
  2 in total

Review 1.  Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.

Authors:  Valentin Fuster; Sarina van der Zee; Marc A Miller
Journal:  J Cardiovasc Transl Res       Date:  2009-10-16       Impact factor: 4.132

2.  Relation of 99mTc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy.

Authors:  Satoshi Isobe; Satoru Ohshima; Kazumasa Unno; Hideo Izawa; Katsuhiko Kato; Akiko Noda; Akihiro Hirashiki; Toyoaki Murohara
Journal:  J Nucl Cardiol       Date:  2010-07-16       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.